Waisman Biomanufacturing partners with Heat Biologics to manufacture COVID-19 vaccine – Mirage News

Waisman Biomanufacturing staff operate a centrifuge that allows for cell separation. The UW-Madison biopharmaceutical contract manufacturer is partnering with Heat Biologics to produce a COVID-19 vaccine for phase 1 and phase 2 clinical trials. Todd Brown, Media Solutions, UW School of Medicine and Public Health
Waisman Biomanufacturing at the University of Wisconsin-Madison is partnering with Heat Biologics to produce a COVID-19 vaccine for phase 1 and phase 2 clinical trials. Phase 1 trials c…

Click here to view the original article.